Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
This comparison outlines 2024 tax treatment differences between dividends from ETFs and mutual funds for informed decisions.
24,763 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
A 67-year-old retiree’s $1.9 million portfolio shed 21% during a broad market pullback, yet a cash-and-Treasury ladde...
SkyX’s Q1 2026 results hint at a company in transition: solid top-line momentum paired with ongoing investments. This...
We unpack the Q4 results and what ftai (fip) 2025 earnings imply for the year ahead. Learn the key drivers, risk fact...
Lucid Diagnostics (LUCD) is navigating reimbursement and adoption as it scales its non-invasive tests. This analysis ...
BioCryst faces a pivotal year. This practical guide breaks down what biocryst (bcrx) 2026 earnings could mean for inv...
Take a practical tour of arcutis (arqt) 2026 earnings, from revenue mix and margins to pipeline progress and risk fac...
Institutional moves can reveal where smart money sees durable cash flow. Learn why ancora advisors opens $148 million...
A rare market signal is flashing. This article breaks down the CAPE warning, what history suggests, and how to guard ...
A wave of AI-driven job cuts is changing where and how people buy homes. This guide breaks down what ai-created tech ...
A single smart decision can snowball into financial freedom. Learn the small sacrifices that gave me 25 rentals and a...
A single viral moment can grab attention, but your hardest-hitting finance lessons come from everyday decisions. Lear...